Quote | Chemomab Therapeutics Ltd. (NASDAQ:CMMB)
Last: | $0.969 |
---|---|
Change Percent: | 0.0% |
Open: | $0.9419 |
Close: | $0.969 |
High: | $0.9701 |
Low: | $0.9101 |
Volume: | 13,900 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Chemomab Therapeutics Ltd. (NASDAQ:CMMB)
—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting the Potential of Chemomab’s CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC— ...
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug’s Direct Interference with Liver Fibroblast Activation— — New Translational Data Further Confirms CM-101’s ...
Message Board Posts | Chemomab Therapeutics Ltd. (NASDAQ:CMMB)
Subject | By | Source | When |
---|---|---|---|
short data if anyone is interested | Distantpulse | investorshub | 06/25/2023 1:08:37 PM |
Lol for real! | Distantpulse | investorshub | 06/22/2023 12:58:56 PM |
Its a dog with fleas! lol | subslover | investorshub | 06/22/2023 12:58:13 PM |
And it still crashes.smfh. | Distantpulse | investorshub | 06/22/2023 12:55:41 PM |
MomentumIts trading last trade up | crudeoil24 | investorshub | 06/21/2023 7:31:39 PM |
News, Short Squeeze, Breakout and More Instantly...
Chemomab Therapeutics Ltd. Company Name:
CMMB Stock Symbol:
NASDAQ Market:
Chemomab Therapeutics Ltd. Website:
—Proteomic Analysis of Patient Samples Further Confirms that CCL24 is Associated with Primary Sclerosing Cholangitis (PSC) Severity and Progression, Highlighting the Potential of Chemomab’s CCL24-Neutralizing Antibody CM-101 as a Promising Therapy for PSC— ...
—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug’s Direct Interference with Liver Fibroblast Activation— — New Translational Data Further Confirms CM-101’s ...